Eli Lilly and Company (LLY)vsUtah Medical Products Inc (UTMD)
LLY
Eli Lilly and Company
$1,372.99
+6.57%
HEALTHCARE · Cap: $1.12T
UTMD
Utah Medical Products Inc
$68.84
-5.78%
HEALTHCARE · Cap: $231.97M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 228052% more annual revenue ($79.67B vs $34.92M). LLY leads profitability with a 33.5% profit margin vs 30.5%. LLY appears more attractively valued with a PEG of 1.14. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
UTMD
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
-49.3%
Fair Value
$42.70
Current Price
$68.84
$26.14 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 34.8%
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 36.1x book value
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Revenue declined 12.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : UTMD
The strongest argument for UTMD centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 30.5% and operating margin at 34.8%.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 42.2x leaves little room for execution misses. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : UTMD
The primary concerns for UTMD are Market Cap, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
LLY profiles as a growth stock while UTMD is a declining play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.45 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 54/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Utah Medical Products Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Utah Medical Products, Inc. develops, manufactures and distributes medical devices for the healthcare industry. The company is headquartered in Midvale, Utah.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?